Notice to Long-Term Shareholders of Amylyx Pharmaceuticals, Inc. (AMLX): Grabar Law Office is Investigating Claims on Your Behalf as Securities Fraud Class Action Survives Motion to Dismiss

If you purchased Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever.
Please visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call us at 267-507-6085 to learn more.

WHY? The underlying complaint alleges that, Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), through certain of its officers and directors, made materially false and misleading statements regarding the Company's business, operations, and prospects in that: (i) Defendants had overstated Relyvrio's commercial prospects; (ii) patients were discontinuing treatment with Relyvrio after six months; (iii) the rate at which new patients were starting treatment with Relyvrio was decreasing; (iv) accordingly, Defendants had also overstated Relyvrio's prescription rate; (v) Defendants attempted to hide the foregoing negative trends from investors and the market by blocking analysts from viewing Relyvrio's prescription data; and (vi) as a result, Defendants' public statements were materially false and misleading at all relevant times. Then on April 4, 2024, Amylyx announced it was pulling Relyvrio from the market.

On September 30, 2025, the court determined that certain key allegations survived the defendants' motion to dismiss the underlying class action complaint.

WHAT YOU CAN DO NOW: If you purchased Amylyx Pharmaceuticals, Inc., (NASDAQ: AMLX) prior to May 11, 2023, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/amylyx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. $AMLX #Amylyx

Attorney Advertising Disclaimer

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/271317